We assembled a panel of eleven patient-derived molecularly heterogeneous BTIC cultures with previously reported status of common GBM molecular alterations including MGMT promoter methylation, EGFR, PTEN, TP53, NF1, IDH1, and CDKN2A mutations [24,27] (S1 Table). This evidence concerns the gene TP53 and glioblastoma.